egnite 2026 Benchmark Report: Four-Class GDMT Prescribing in Systolic Heart Failure More Than Doubles, Yet Four in Five Patients Are Not Prescribed Full Guideline Therapy

In egnite's observational analysis of more than 650,000 U.S. systolic heart failure patients, three-year survival was 76% for patients prescribed all four GDMT classes versus 52% for those prescribed none, an association rather than evidence of causation. Four-class prescribing rose from 9% in the 2023 report to 21%, but 79% of patients still were not on all four classes. The report also found only 7% of eligible symptomatic severe tricuspid regurgitation patients received treatment, despite two FDA approvals in 2024.

Analysis

The investable signal is an implementation gap, not proof that the reported survival difference will translate into an equivalent treatment effect or revenue pool. The survival comparison is observational and may reflect patient selection, disease severity, or ability to tolerate therapy; moreover, the 2023-to-2026 prescribing comparison is not a matched-site panel. Treat the 79% not on four-class therapy as a ceiling on potential uptake, not a forecast.

Over 1–3 months, the TCT presentation could sharpen the structural-heart opportunity, but current TR treatment penetration is a caution: FDA approvals have not yet produced broad adoption. That points to referral pathways, diagnosis, reimbursement, and procedural capacity—not just device availability—as constraints. Device makers such as Abbott, Edwards Lifesciences, and Medtronic could benefit if adoption accelerates, but this release alone does not establish that catalyst. Over 6–18 months, better identification and follow-up of HF and valve patients could support demand for care-management software and SGLT2 inhibitors, including products from AstraZeneca and Boehringer Ingelheim/Eli Lilly; incremental drug sales depend on actual prescribing and persistence, not the untreated population count.

The contrarian risk is that investors overread a compelling outcomes association as near-term commercial acceleration. The company’s platform claims and single-site improvement are not independently verified evidence of scalable system-wide economics. No supplied public-company mapping identifies egnite, so there is no direct ticker-level trade here.

Key Decisions for Investors

• No immediate broad healthcare or pharma trade on this release. Use the report as a diligence lead; require independent prescription, persistence, and reimbursement data before underwriting incremental SGLT2 sales.
• Watch AstraZeneca and Boehringer Ingelheim/Eli Lilly exposure as a conditional demand theme. Upgrade only if claims or prescription data show sustained growth in multi-class HFrEF therapy; falsify the thesis if uptake stalls despite further health-system outreach.
• Keep Abbott, Edwards Lifesciences, and Medtronic on a structural-heart watchlist rather than buying the announcement. Reassess after TCT for evidence that untreated symptomatic patients are converting into referrals and procedures; persistent low TR treatment penetration would weaken the adoption case.
• For the 1–3 month catalyst window, track TCT disclosures, reimbursement and referral changes, and health-system implementation evidence. For a 6–18 month thesis, look for matched-site GDMT adoption and reduced HF admissions; without those measures, treat the report as a non-trade.